Nathaniel Whaley, MD
Neurology · Johnson City, TNNPI 1245213545
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2019 at $56,683 and has fallen 91.9% since, to $4,615 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,519 payments — averaging $91.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$27K
- Biohaven Pharmaceuticals, Inc.$19K
- Biogen$18K
- Argenx US, Inc.$14K
- AstraZeneca$11K
- AbbVie$9K
- plus $40K from 54 others
Across 71 payments — averaging $8736.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$386K
- Adamas Pharmaceuticals, Inc.$150K
- Eli Lilly$46K
- Amgen$38K
What the payments were for
- Consulting fees$30,10022%
- Speaking & faculty fees$69,80050%
- Travel & lodging$9,8997%
- Food & beverage$28,68121%
- Education$2860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,765 in reported general payments places this provider in the 90th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 13 | $405,575 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 31 | $332,104 |
| NuplazidPimavanserin Tartrate | 30 | $198,733 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $179,802 |
| BotoxOnabotulinumtoxina | 105 | $177,404 |
| IngrezzaValbenazine Tosylate | 14 | $111,658 |
| Teriflunomide | 71 | $71,476 |
| BriviactBrivaracetam | 47 | $67,891 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $58,582 |
| Aimovig AutoinjectorErenumab-Aooe | 57 | $43,313 |
| GocovriAmantadine Hcl | 18 | $40,880 |
| AptiomEslicarbazepine Acetate | 11 | $32,853 |
| Emgality PenGalcanezumab-Gnlm | 34 | $24,892 |
| FycompaPerampanel | 19 | $21,703 |
| NeuproRotigotine | 24 | $21,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $583 | $347,78844 claims |
| Acadia Pharmaceuticals IncNuplazid | $567 | $198,73330 claims |
| CSL BehringPrivigen | $480 | $179,80232 claims |
| AbbVieBotox | $9,392 | $177,404105 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $828 | $111,65814 claims |
| UCB, Inc.Briviact, Neupro | $1,827 | $89,15071 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $26,724 | $58,58234 claims |
| MDD US Operations, LLCGocovri | $1,021 | $40,88018 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $291 | $32,85311 claims |
| Eisai Inc.Fycompa | $691 | $21,70319 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $346 | $8,37585 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $183 | $5,70911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 361 neurology providers in Tennessee.
Other neurology in Johnson City
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
- Khalid AlsherbiniMemphis$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.